(MENAFN- ProactiveInvestors)
( NASDAQ:PBMD) is making strides in the growing Immuno-Oncology field of cancer treatment which is potentially a US$35 billion market by 2025.
Last month shares in the company increased almost ten-fold.
Stuart Roberts Global Head of Investor Relations for outlined the company's latest developments at Proactive's Sydney / Melbourne Luncheons this week.
ACCESS PRESENTATION HERE:
Prima's original product CVacTM is a cancer vaccine with favourable clinical data in second-remission ovarian cancer.
Prima is receiving an investment of $15 million from Ridgeback Capital Investments to fund commencement of two clinical trials for its IMP321 treatment for cancer.
Proactive Investors Australia is the market leader in producing news articles and research reports on ASX emerging companies with distribution in Australia UK North America and Hong Kong / China.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.